Skip to main content

Month: November 2020

Fynske Bank A/S: Storaktionærmeddelelse

Selskabsmeddelelse nr. 2020/16Strategic Investments A/S oplyser i medfør af § 29 i Lov om Værdipapirhandel, at selskabet den 27. november 2020 har erhvervet yderligere 6.837 stk. aktier i Fynske Bank A/S.  Selskabets samlede aktie-besiddelse udgør herefter i alt 760.000 stk., svarende til 10,03% af aktiekapitalen.For yderligere information, kontakt venligst:Adm. direktør Petter Blondeau, tlf. 6217 6501 eller 6168 0501.Med venlig hilsenFynske Bank A/SVedhæftet filSelskabsmeddelelse 2020-16

Continue reading

DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies

Initial funding of up to $34 million for the project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus” (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAbTM through Phase 2 clinical studies.STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.STI-2020-encoded Gene MAb products can potentially be stored at refrigerator temperatures, avoiding some of the cold chain management challenges associated with the deployment of COVID-19 vaccines currently in development.  Sorrento has a cGMP facility in place to meet initial production demand and Sorrento expects that STI-2020-encoded Gene MAb can be produced in large quantity to meet potentially high demand.SAN...

Continue reading

Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:Evercore ISI 3rd Annual HealthCONx ConferenceDate: December 1, 2020Live Presentation Time: 10:55 am ETPiper Sandler 32nd Annual Virtual Healthcare ConferenceDate: December 2, 2020Pre-recorded presentation available onlineExecutive management will also participate in one-on-one meetings during the duration of the conferences.To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations....

Continue reading

NanoXplore Announces Appointment of New Board Member

MONTREAL, Nov. 27, 2020 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore” or the “Corporation”) (TSX-V: GRA and OTCQX: NNXPF) is pleased to announce the appointment of Jodie Morgan to its Board of Directors.Ms. Morgan has an impressive background as a strategic President and CEO and Board member of several companies, including currently as a Director of Bartek Ingredients Inc., the world’s largest producer of malic acid and food-grade fumaric acid—specialty products that improve flavour profiles, food safety and profitability in foods and beverages, among other things. She is also currently the CEO and a Director of GreenMantra, an upcycling technology leader in the circular economy of plastics. Ms. Morgan is a member of the National Association of Corporate Directors and Women Corporate Directors in the United States...

Continue reading

NanoXplore annonce la nomination d’un nouveau membre à son conseil d’administration

MONTRÉAL, 27 nov. 2020 (GLOBE NEWSWIRE) — NanoXplore Inc. (« NanoXplore » ou la « Société ») (TSX-V: GRA et OTCQX: NNXPF) a le plaisir d’annoncer la nomination de Jodie Morgan à son conseil d’administration.Mme Morgan a une expérience impressionnante en tant que présidente et chef de la direction et membre du conseil d’administration de plusieurs entreprises, y compris actuellement en tant qu’administratrice de Bartek Ingredients Inc., le plus grand producteur mondial d’acide malique et d’acide fumarique de qualité alimentaire – des produits spécialisés qui améliorent la saveur, la sécurité alimentaire et la rentabilité des aliments et des boissons, entre autres. Elle est également chef de la direction et administratrice de GreenMantra, un leader de la technologie « upcycling » dans l’économie...

Continue reading

Cypress Development Announces Extension to Nevada Option Agreement with Pasinex

VANCOUVER, British Columbia, Nov. 27, 2020 (GLOBE NEWSWIRE) — Cypress Development Corp. (TSX-V: CYP) (OTCQB: CYDVF) (Frankfurt: C1Z1) (“Cypress” or “the Company”) announces the Company has reached an agreement with Pasinex Resources Limited (CSE: PSE) (“Pasinex”) and Caliber Minerals Inc. to change the terms relating to the earn-in option agreement on Cypress’ Gunman (formally Spur) zinc exploration property in Nevada, USA.The agreement extends the deadline to complete the conditions to earn an initial 51% interest in the Gunman Project to December 31, 2022 and extends the deadline to complete the conditions to earn an additional 29% interest in the Gunman Project to December 31, 2024.As a condition precedent for the effectiveness of the agreement and as a binding and unconditional material obligation, Pasinex shall incur a minimum...

Continue reading

Spectral Medical to Host Virtual Investor Day on December 4, 2020

TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. (“Dialco”), today announced the details for the Company’s upcoming Virtual Investor Day, scheduled to be held on Friday, December 4, 2020 at 10:00 a.m. EST.Members of Spectral’s leadership team will provide a detailed status update on the progress of the Tigris trial as well as the approvals and advancements towards commercialization at Dialco. In addition, the Company will provide commentary on its balance sheet and the capital markets environment.To preregister for the webcast presentation,...

Continue reading

Trident Acquisitions Files Proxy Supplement Detailing Terms for Extension of Business Combination Deadline

NEW YORK, Nov. 27, 2020 (GLOBE NEWSWIRE) — Trident Acquisitions Corp. (NASDAQ: TDACU, TDAC, TDACW) (“Trident”), a special purpose acquisition company, announced that it has filed a proxy supplement to its annual meeting proxy statement (the “Supplement”). The Supplement explains certain changes to the terms under which Trident can extend its available time to complete a business combination. If stockholders approve the amendment to Trident’s certificate of incorporation at the November 30, 2020 stockholder’s meeting (the “Annual Meeting”), which allows Trident the ability to extend the date by which it has to complete a business combination by an additional three months and with an ability to further extend for an additional three months if approved by Trident’s board of directors, Trident will be required to deposit additional...

Continue reading

CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies

MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish & Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy – Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&D.About Ocugen, Inc.Ocugen, Inc. is a biopharmaceutical company...

Continue reading

Toilet Paper Market to Reach USD 38.34 Billion by 2027; Rising Awareness of Deforestation to Augment Growth, says Fortune Business Insights™

Pune, India, Nov. 27, 2020 (GLOBE NEWSWIRE) — The global toilet paper market is set to gain momentum from the rising awareness of deforestation while producing paper pulp. This information is given by Fortune Business Insights™ in a new report, titled, “Toilet Paper Market Size, Share & COVID-19 Impact Analysis, By Type (Rolled and Folded), Ply Count (One, Two, and Others), Application (Household, Healthcare, Hospitality, and Others), and Regional Forecast, 2020-2027.” The report further states that the market size was USD 26.14 billion in 2019 and is projected to reach USD 38.34 billion by 2027, exhibiting a CAGR of 4.9% during the forecast period.COVID-19 Pandemic to Accelerate Growth Fueled by Panic Buying among MassesThe outbreak of the COVID-19 pandemic created panic buying practices among the masses in the first few months...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.